▎Edited by the WuXi AppTec content teamAccording to incomplete statistics from Innovation Insights, last week (April 7 to April 13) in the global health and wellness fieldA total of 28 financing events were disclosed, with a total amount exceeding 4.4 billion yuan.。In terms of amount, there were 7 financings of 100 million yuan or more.According to the disclosed financing rounds, there were 14 early-stage financings (before Series B) and 6 mid-to-late stage financings (Series B and later). A total of 8 companies in the biopharmaceutical field received financing, involving drug types including antibody drugs, cell therapies, small nucleic acid drugs, etc.Merida Biosciences Secures $121 Million in Financing
Keywords:Antibody Drugs
LatestIntegrationResources：$121 Million Series A
This roundInvestment Institutions:BVF Partners、Bain Capital Life Sciences、GV、Perceptive Xontogeny Venture FundApril 8,The Latest Biotech Company Launched by Third Rock VenturesSecured $121 million in Series A financing.Merida Therapeutics was founded by Third Rock in 2022, when the biotech company's co-founder and chief scientific officer, Dr. Dario Gutierrez, was serving as an entrepreneur-in-residence at the venture capital firm.The company's main preclinical project targets Graves' disease, an autoimmune disorder that causes the body to produce antibodies attacking the thyroid. The company’s early-stage development projects includeAn Antibody for Allergic Diseases, which aims to neutralize and eliminate IgE antibodies. Merida Biosciences is also developing a therapy for the treatment of a chronic inflammatory kidney disease known as primary membranous nephropathy.Solu Therapeutics Completes $41 Million Series A Financing
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Keywords:Bifunctional Small Molecule Drugs
Latest Financing：$41 Million Series A
This roundInvestment Institutions:Alexandria Venture Investments, Astellas Venture Management, Biovision Ventures, Eli Lilly and Company, etc.April 9,Solu Therapeutics Announces $41 Million Series A Financing to Advance STX-0712 Clinical Evaluation, Expand Pipeline, and Explore New Applications for Cytotoxicity Targeted Chimeras and Therapeutic Index-Controlled Targeted Chimeras (TicTAC) Platforms. The company also announced the initiation of a Phase 1 clinical trial for STX-0712 in treating resistant/refractory chronic myelomonocytic leukemia (CMML) and other hematologic malignancies, with the first patient dosing now underway.Solu Therapeutics connects potent, selective small molecules with effector antibodies in a unique way., which can target cell surface proteins (such as G protein-coupled receptors and ion channels) that are difficult for traditional therapies to address. One arm of its bifunctional small molecule can specifically enter deep binding pockets in cell surface proteins, while the other arm is linked to its proprietary antibody through a proprietary linker technology, enhancing the efficacy of the effector antibody.Solu Therapeutics Completes Nearly 100 Million Yuan in Financing
Keywords:Stem Cell Therapy
LatestIntegrationCapital:Nearly 100 Million Yuan B+ Round
This roundInvestment Institutions:Fengchuan Capital, Hetang VenturesApril 11 Day ConsumptionRecently, Solu Therapeutics announced the completion of its B+ round of financing. The funds from this round will be used to accelerate the clinical advancement of Solu Therapeutics' Parkinson's disease treatment products NouvNeu001/NouvNeu003 and ophthalmic treatment product NouvSight001 in both China and the United States, as well as to strengthen the company’s R&D progress for multiple innovative pipelines and the establishment of clinical capabilities. Founded in 2017, Solu Therapeutics is an innovative biopharmaceutical company focused on the field of regenerative medicine.Through a unique technical platform, focusing on small molecule chemical transcription regulation-induced pluripotent stem cells(iPSC), thereby developing universal chemically induced cell therapy drugs. NouvNeu001 injection is a type of chemically induced functional human dopaminergic neuron precursor cell developed by Solu Therapeutics, which received approval from China's NMPA in August 2023 to conduct combined Phase 1-2 clinical research.Solu Therapeutics Completes Angel+ Round of Financing Worth Tens of Millions of Yuan
Keywords:BigMolecular MedicineDelivery
LatestIntegrationCapital:Tens of Millions of YuanAngel+ Round
This roundInvestment Institutions:CAS StarRecently,Saiyun Biotech, a biotechnology company focusing on cutting-edge international delivery carrier technologies and innovative drug therapies, announced the completion of an angel+ round of financing worth tens of millions. The funds raised from this round will mainly be used to accelerate the development process of the company's self-developed pipeline.Solu Therapeutics is a company focused on the development of targeted delivery technologies and innovative drug therapies., successfully developed a class of bionic delivery systems with independent intellectual property rights. Different from mainstream delivery carrier systems, this system, after rational modification, can achieve precise cellular delivery of various types of payloads and has significant advantages in specificity recognition, payload compatibility, protection, and production cost.Solu Therapeutics Secures Tens of Millions of Yuan in Series B Financing
Keywords:Pluripotent Stem Cells
MostNewIntegrationResources:Tens of Millions of Yuan in Series B
This roundInvestment Institutions:Hefei Industrial Investment Capital, Guangzhou Pharmaceutical Capital, Sci-Tech Gold Holdings, Hanyuan AssetsRecently, Solu Therapeutics announced that it has received tens of millions of yuan in funding support in its Series B round.Solu Therapeutics has long been laying out product pipelines involving multiple cell types and indications in the three cutting-edge medical fields of regenerative medicine, anti-inflammatory repair, and tumor immunology.Five have been approved to enter the registration clinical trial, including the first iMSC and iNK cell therapy products in China, as well as the world's first gene-modified iMSC product.Currently, the product pipelines for the treatment of knee osteoarthritis, two hematological tumor indications, graft-versus-host disease, and interstitial lung disease indications are respectively in Phase I and Phase II clinical trials. In the future, the company will accelerate the registration and clinical research of multiple iPSC-derived cellular products, with the hope of achieving commercial application of the products as soon as possible to bring more treatment options to patients.Readers, please star ⭐Chuangjianhui to receive updates第一时间收到推送.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views mentioned in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.
Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media feeds, but unauthorized re-posting or reproduction by media or institutions in any form to other platforms is strictly prohibited. For re-posting authorization, please contact"InnoVantage"Contact us by leaving a message on our WeChat Official Account.
More Data Content RecommendationsClick "InSee", Sharing Chuangjianhui Health New Trends
